AVCT.L
Healthcare BiotechnologyAvacta Group Plc
£72.00
+0.00 +0.00% today Live
Price History
Not enough data
| Date | Price |
|---|---|
| Oct 5, 2026, live at 10:55 AM ET | 72.00 |
Key Stats
Market Cap
32.90B
Avg Volume
1.09M
EPS
-£0.09
52W High
£92.00
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-13.72
P/B Ratio
90.00
P/S Ratio
2911.61
EV/EBITDA
-11.27
EV/Revenue
2982.79
Margins
Gross Margin 100.0%
Operating Margin (24419.6%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
0.0%
Return on Equity
(1965.1%)
Return on Assets
(62.4%)
Liquidity & Leverage
Current Ratio
0.95
Quick Ratio
0.95
Debt / Equity
5.27
Total Cash
20.27M
Total Debt
19.86M
About
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
avacta.com